Recursive Language Models aim to break the usual trade off between context length, accuracy and cost in large language models. Instead of forcing a model to read a giant prompt in one pass, RLMs treat ...

Dec. 23 (Asia Today) --Some North Korean-born people of Chinese descent become effectively stateless as soon as they arrive in South Korea, rights advocates and defectors say, because authorities do ...

According to DeepLearning.AI, Samsung’s Tiny Recursive Model (TRM) utilizes iterative answer refinement and maintains a context of previous changes to tackle complex grid puzzles such as Sudoku, Mazes ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Six friends enter a cave system looking for a spelunking adventure, but the creatures that await them are hungry for blood. Jen Karner has spent the last 10 years covering technology, streaming ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) traded higher in the premarket on Tuesday after the AI-driven biotech announced plans to reduce its workforce by approximately 20% as part of a ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...